Literature DB >> 2014525

Transplantation of encapsulated allogeneic islets into diabetic BB/W rats. Effects of immunosuppression.

R Mazaheri1, P Atkison, C Stiller, J Dupré, J Vose, G O'Shea.   

Abstract

Allogeneic islets obtained from Lewis rats were transplanted into diabetic BB/W rats with or without cyclosporine. In addition, these islets were encapsulated in alginate-poly L-lysine membranes and then transplanted into diabetic BB/W rats with or without immunosuppressive and/or antiinflammatory agents. The agents used were cyclosporine, dexamethasone, indomethacin (Ind), or a combination of these. Our results show that islets alone survived for 7 days, with or without CsA therapy. Encapsulated islets survived for 14.2 days, and this was extended by CsA, Dex, or CsA + Ind. Loss of encapsulated graft functions was associated with formation of a dense pericapsular infiltrate, which was inhibited by CsA, Dex, CsA + Ind, or CsA + Dex. In addition, the infiltrate was reduced in animals that had diabetes for long periods of time (greater than 5 months versus less than 1 month). Empty capsules also provoked this cellular response. Thus, encapsulation of islets resulted in slightly prolonged islet survival, which was further enhanced by immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014525     DOI: 10.1097/00007890-199104000-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Prolongation of the normoglycemic period in animals with acute experimental diabetes by means of various types of tissue transplantation.

Authors:  A V Kulikov; G T Sukhikh; L V Arkhipova; G N Smirnova; R A Poltavtseva; T M Tret'yak; L I Kulikova; L M Chailakhyan
Journal:  Dokl Biol Sci       Date:  2001 Jul-Aug

2.  Microencapsulated islet grafts in the BB/E rat: a possible role for cytokines in graft failure.

Authors:  D R Cole; M Waterfall; M McIntyre; J D Baird
Journal:  Diabetologia       Date:  1992-03       Impact factor: 10.122

3.  Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient.

Authors:  D Jacobs-Tulleneers-Thevissen; M Chintinne; Z Ling; P Gillard; L Schoonjans; G Delvaux; B L Strand; F Gorus; B Keymeulen; D Pipeleers
Journal:  Diabetologia       Date:  2013-04-26       Impact factor: 10.122

4.  Lymphoid activation by micro- and macroencapsulated islets during mixed lymphocyte islet culture.

Authors:  T Zekorn; H Entenmann; A Horcher; U Siebers; G Klöck; U Zimmermann; K Federlin; R G Bretzel
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

Review 5.  Islet microencapsulation: a review.

Authors:  H A Clayton; R F James; N J London
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

6.  Alginate coating of islets of Langerhans: in vitro studies on a new method for microencapsulation for immuno-isolated transplantation.

Authors:  T Zekorn; U Siebers; A Horcher; R Schnettler; U Zimmermann; R G Bretzel; K Federlin
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

7.  Production of purified alginates suitable for use in immunoisolated transplantation.

Authors:  G Klöck; H Frank; R Houben; T Zekorn; A Horcher; U Siebers; M Wöhrle; K Federlin; U Zimmermann
Journal:  Appl Microbiol Biotechnol       Date:  1994-01       Impact factor: 4.813

8.  Cross-linking properties of alginate gels determined by using advanced NMR imaging and Cu(2+) as contrast agent.

Authors:  B Manz; M Hillgärtner; H Zimmermann; D Zimmermann; F Volke; U Zimmermann
Journal:  Eur Biophys J       Date:  2003-09-16       Impact factor: 1.733

9.  Effects of Composition of Alginate-Polyethylene Glycol Microcapsules and Transplant Site on Encapsulated Islet Graft Outcomes in Mice.

Authors:  Chiara Villa; Vita Manzoli; Maria M Abreu; Connor A Verheyen; Michael Seskin; Mejdi Najjar; R Damaris Molano; Yvan Torrente; Camillo Ricordi; Alice A Tomei
Journal:  Transplantation       Date:  2017-05       Impact factor: 4.939

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.